{Reference Type}: Journal Article
{Title}: Marked hyperferritinemia in critically ill cancer patients.
{Author}: Liedgens P;Heger JM;Sieg N;Garcia Borrega J;Naendrup JH;Simon F;Johannis W;Hallek M;Shimabukuro-Vornhagen A;Kochanek M;Böll B;Eichenauer DA;
{Journal}: Eur J Haematol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 27
{Factor}: 3.674
{DOI}: 10.1111/ejh.14263
{Abstract}: <B>OBJECTIVE: </B>To investigate characteristics and outcomes of critically ill cancer patients with marked hyperferritinemia.<BR><B>METHODS: </B>A single-center retrospective analysis comprising cancer patients with a ferritin level >10.000 μg/L treated in the intensive care unit (ICU) between 2012 and 2022 was conducted.<BR><B>RESULTS: </B>A total of 117 patients were included in the analysis. The median age was 59 years (range: 15-86 years). Females accounted for 48% of cases. 90% of patients had a hematologic malignancy. The median maximum ferritin level was 27.349 μg/L (range: 10.300-426.073 μg/L). The diagnostic criteria of septic shock were fulfilled in 51% of cases; 31% of patients had hemophagocytic lymphohistiocytosis (HLH) according to the HLH-2004 criteria. Mechanical ventilation, renal replacement therapy and the use of vasopressors were necessary in 59%, 35% and 70% of cases, respectively. The ICU, hospital, 90-day and 1-year survival rates were 33.3%, 23.1%, 23.7% and 11.7%. Patients with septic shock had a worse survival than those without septic shock (p = .001); the survival of patients who fulfilled the HLH-2004 criteria did not differ from those who did not (p = .88).<BR><B>CONCLUSIONS: </B>Critically ill cancer patients with marked hyperferritinemia have poor outcomes. The present data may help to make informed decisions for this patient group.